Silence Therapeutics Q3 2026 Financial Results and Merck KGaA Acquisition
Silence Therapeutics reported improved Q3 2026 financial metrics and announced an acquisition by Merck KGaA, which could reshape its gene-silencing pipeline and competitive landscape.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed